Alaunos Therapeutics, Inc. reported a net loss of $4.2 million for the fiscal year ending December 31, 2025, a decrease from a net loss of $4.7 million in the previous year. The company has not generated any product revenue since its inception, with minimal collaboration revenue of $5,000 in 2025 compared to $10,000 in 2024. As of December 31, 2025, Alaunos had an accumulated deficit of approximately $924.6 million and cash and cash equivalents of $1.4 million, which the company anticipates will fund operations into the second quarter of 2026. The company’s operating expenses decreased to $4.2 million from $4.8 million in 2024, primarily due to reduced general and administrative costs following significant workforce reductions.
In August 2023, Alaunos announced a strategic reprioritization, shifting its focus from oncology cell therapies to developing a preclinical small-molecule program targeting obesity and metabolic disorders. This transition involved a workforce reduction of approximately 95% and the wind-down of its TCR-T Library Phase 1/2 Trial. The company has since concentrated on advancing its obesity program, which includes the lead candidate ALN1003. Recent preclinical studies demonstrated promising results, including significant body weight loss and improvements in metabolic biomarkers in diet-induced obesity mouse models.
Operationally, Alaunos has not generated significant revenue and continues to rely on external funding to support its research and development efforts. The company has engaged in various financing activities, including the issuance of Series A-1 and A-2 Convertible Preferred Stock, which raised a total of $1.35 million. However, the company faces ongoing challenges in securing additional capital, which is critical for advancing its obesity program and maintaining compliance with Nasdaq listing requirements. As of December 31, 2025, Alaunos' stockholders' equity was reported at $2.2 million, below the $2.5 million minimum required for continued listing on the Nasdaq Capital Market.
Looking ahead, Alaunos plans to continue its focus on the obesity and metabolic disorders program, with the goal of advancing ALN1003 through further preclinical studies and into IND-enabling activities. The company acknowledges the inherent risks associated with early-stage drug development and the need for substantial additional capital to sustain its operations. Management has expressed concerns regarding the company's ability to continue as a going concern if it cannot secure the necessary funding. The company is actively exploring strategic financing and collaboration opportunities to support its development efforts.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing small molecule oral drugs to treat obesity and metabolic disorders. Its lead candidate, ALN1001, aims to offer a differentiated profile by avoiding hormonal manipulation common in current treatments. The company leverages outsourced manufacturing and proprietary research to address unmet needs in weight management, targeting global markets with scalable, non-invasive therapeutic solutions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.